Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children's nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline pl
Bristol Myers Squibb Co.
NYSE:BMY ISIN:US1101221083
ニュース
大正製薬(TYO:4535)が水曜に伝えたところによると、同社はアジア太平洋(中国、日本を含む)における市販薬品関連資産3億1000万米ドル相当をBristol-Myers Squibb Co.(NYSE:BMY)より買収する計画である。
###
19,049 会社概要の閲覧回数
- 日本語ページ閲覧回数: (過去7日間: 6) (過去30日間: 31) (発行以降: 4584)